Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
OmpA controls order in the outer membrane and shares the mechanical load.
Benn G, Borrelli C, Prakaash D, Johnson ANT, Fideli VA, Starr T, Fitzmaurice D, Combs AN, Wühr M, Rojas ER, Khalid S, Hoogenboom BW, Silhavy TJ. Benn G, et al. Among authors: fitzmaurice d. Proc Natl Acad Sci U S A. 2024 Dec 10;121(50):e2416426121. doi: 10.1073/pnas.2416426121. Epub 2024 Dec 4. Proc Natl Acad Sci U S A. 2024. PMID: 39630873 Free PMC article.
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J, Kim S, Kwon J, Jones L, Hirst JA, Yu LM, Mort S; BARACK-D Investigators; BARACK-D Investigators; Regional coordinating centre teams. Hobbs FDR, et al. Nat Med. 2024 Dec;30(12):3634-3645. doi: 10.1038/s41591-024-03263-5. Epub 2024 Sep 30. Nat Med. 2024. PMID: 39349629 Clinical Trial.
Cluster randomised controlled trial of screening for atrial fibrillation in people aged 70 years and over to reduce stroke: protocol for the pilot study for the SAFER trial.
Williams K, Modi RN, Dymond A, Hoare S, Powell A, Burt J, Edwards D, Lund J, Johnson R, Lobban T, Lown M, Sweeting MJ, Thom H, Kaptoge S, Fusco F, Morris S, Lip G, Armstrong N, Cowie MR, Fitzmaurice DA, Freedman B, Griffin SJ, Sutton S, Hobbs FR, McManus RJ, Mant J, Safer Authorship Group T. Williams K, et al. Among authors: fitzmaurice da. BMJ Open. 2022 Sep 9;12(9):e065066. doi: 10.1136/bmjopen-2022-065066. BMJ Open. 2022. PMID: 36691194 Free PMC article.
Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.
Hill NR, Lasserson D, Thompson B, Perera-Salazar R, Wolstenholme J, Bower P, Blakeman T, Fitzmaurice D, Little P, Feder G, Qureshi N, Taal M, Townend J, Ferro C, McManus R, Hobbs FDR. Hill NR, et al. Among authors: fitzmaurice d. Trials. 2022 Dec 12;23(1):999. doi: 10.1186/s13063-022-06972-9. Trials. 2022. PMID: 36510220 Free PMC article. No abstract available.
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.
Haas S, Camm JA, Harald D, Steffel J, Virdone S, Pieper K, Brodmann M, Schellong S, Misselwitz F, Kayani G, Kakkar AK; GARFIELD-AF Investigators. Haas S, et al. Clin Res Cardiol. 2023 Jun;112(6):759-771. doi: 10.1007/s00392-022-02079-y. Epub 2022 Sep 12. Clin Res Cardiol. 2023. PMID: 36094573
Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF.
Apenteng PN, Virdone S, Hobbs FR, Camm AJ, Fox KA, Pieper KS, Kayani G, Fitzmaurice D; GARFIELD UK investigators*. Apenteng PN, et al. Among authors: fitzmaurice d. Br J Gen Pract. 2022 Feb 18;72(723):e693-701. doi: 10.3399/BJGP.2021.0548. Online ahead of print. Br J Gen Pract. 2022. PMID: 35577587 Free PMC article.
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
Gallagher H, Dumbleton J, Maishman T, Whitehead A, Moore MV, Fuat A, Fitzmaurice D, Henderson RA, Lord J, Griffith KE, Stevens P, Taal MW, Stevenson D, Fraser SD, Lown M, Hawkey CJ, Roderick PJ. Gallagher H, et al. Among authors: fitzmaurice d. Trials. 2022 Apr 21;23(1):331. doi: 10.1186/s13063-022-06132-z. Trials. 2022. PMID: 35449015 Free PMC article.
254 results